Dipyridamole labels and packages: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Dipyridamole}} {{CMG}}; {{AE}} {{SS}} ==Labels and Packages== {| |- |thumb|800px |- |} {| |- |thumb|800px...")
 
No edit summary
Line 6: Line 6:
{|
{|
|-
|-
|[[File:Dipyridamole04.jpg|thumb|800px]]
|[[File:Dipyriamole04.jpg|thumb|800px]]
|-
|-
|}
|}
Line 12: Line 12:
{|
{|
|-
|-
|[[File:Dipyridamole05.jpg|thumb|800px]]
|[[File:Dipyriamole05.jpg|thumb|800px]]
|-
|-
|}
|}
Line 18: Line 18:
{|
{|
|-
|-
|[[File:Dipyridamole06.jpg|thumb|800px]]
|[[File:Dipyriamole06.jpg|thumb|800px]]
|-
|-
|}<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = PERSANTINE (DIPYRIDAMOLE) TABLET, COATED [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca68879c-0214-4d7c-93b0-bdaf8ef23f8e | publisher =  | date =  | accessdate = 7 February 2014 }}</ref>
|}<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = PERSANTINE (DIPYRIDAMOLE) TABLET, COATED [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca68879c-0214-4d7c-93b0-bdaf8ef23f8e | publisher =  | date =  | accessdate = 7 February 2014 }}</ref>

Revision as of 03:16, 7 February 2014

Dipyridamole
PERSANTINE® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Labels and Packages

[1]

References

  1. "PERSANTINE (DIPYRIDAMOLE) TABLET, COATED [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]". Retrieved 7 February 2014.

Template:WikiDoc Sources